Organon & Co. (OGN)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2019
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Women's Health Revenue	1.82B	1.78B
Biosimilars Revenue	673.00M	662.00M
Established Brands Revenue	3.71B	3.85B
Other Product Group Revenue	94.00M	115.00M
Revenue (Total)	6.30B	6.40B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2019
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
United States Revenue	1.65B	1.57B
Europe and Canada Revenue	1.63B	1.76B
Asia Pacific and Japan Revenue	996.00M	1.05B
China Revenue	840.00M	847.00M
Latin America, Middle East, Russia and Africa Revenue	1.08B	1.03B
Other International Revenue	108.00M	137.00M
International Revenue	4.65B	4.83B
Revenue (Total)	6.30B	6.40B

Updated Nov 10, 2025. Data Source: Fiscal.ai.